Cory Renauer
Value, research analyst, biotech, small-cap

Putting Alnylam's Positive ATTR Clinical Data In Context

On Thursday Morning, July 11, Alnylam (NASDAQ:ALNY) shared some very positive data from an ongoing Phase 1 trial of ALN-TTRsc. The market loved the data enough to send its shares soaring 15% before the market opened, where they stayed until the close. After a day to digest the news, the market drove shares even higher, then back to Earth. On Thursday, July 18, shares of Alnylam closed at $42.87, still about 14% higher than its closing price of $37.6 on Wednesday, July 10.

I have to admit I found the initial response to Alnylam's Phase 1 data baffling. Isis Pharmaceuticals (ISIS) is also working on a transthyretin-mediated amyloidosis [ATTR] therapy, and it is much further along....

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
PRO Top long ideas returned 21.7% in 2016**
"As a PRO member, we get uniquely valuable perspective that go beyond our quantiative analysis... We rely on PRO to get beyond the numbers quickly and add much needed perspective. It keeps me ahead of the next big thing. - Mark Choate, Malaga Cove Capital"
Mark Choate, Malaga Cove Capital
"Contributors (writers and commentators), often have a long history in the secuirities they opine on and some are clearly well positioned industry participants with detailed industry views that can help provide color on where the skeletons are buried in a particular secuirity and/or industry."
Jim Roumell, Roumell Asset Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details